AstraZeneca antibody cocktail effective in COVID-19: Study
eMediNexus, 12 October 2021
remove_red_eye 529 Views
#Hospital Medicine #Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine
Coronavirus Live Count Map India
remove_red_eye 529 Views
COVID-19 Vaccine Updates
Coronavirus Protocols
#Hospital Medicine #Infectious Diseases #Pathology and Lab Medicine #Pharmacist #Public Health #Pulmonary Medicine
An experimental COVID-19 antibody drug cocktail developed by AstraZeneca could reduce severe disease or death in non-hospitalized patients in a late-stage study, stated the drug maker on Monday.The drug, known as AZD7442, was found to decrease the risk of developing severe COVID-19 or death by 50% in patients who had been symptomatic for <7 days. Executive vice president, biopharmaceuticals R&D, AstraZeneca, MenePangalos, said that an early intervention with the antibody drug can signific...
Create Account
Login Now
To read the complete article ,
create a free account.
Sign Up
to instantly read 30000+ free Articles & 1000+ Case Studies
Already registered?
Looks like now; ‘ from Racing COVID vaccines manufacturing >>> we may have a race against COVID Antibody cocktail therapy and oral COVID pills like the Merck Pill selling <<< Good the cost will be quickly come-down for the patients !!!.,